INS and polycystic ovary syndrome: The magnitude of benefit sits shoulder-to-shoulder with metformin for insulin resistance and beats oral contraceptives for metabolic endpoints, all while sporting a mild side-effect profile (International PCOS Network, 2023; Peng et al., 2023; Dason et al., 2024).